Advertisement Daval Aimspro as monotherapy in scleroderma yields positive results - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Daval Aimspro as monotherapy in scleroderma yields positive results

Daval International has reported that its double-blind placebo-controlled phase II clinical study to assess the safety and tolerability of Aimspro as a monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma) yielded positive results.

During the course of the trial, 4.5mg/ml doses of Aimspro was administered subcutaneously twice weekly for 26 weeks and its efficacy was evaluated as compared to a placebo.

The study demonstrated that the drug candidate proved to be a safe, well-tolerated medication and showed no deterioration in haematological, biochemical, immunologic, cardiologic or in pulmonary parameters.

The secondary endpoint comprises assessing the efficacy of Aimspro as a therapeutic agent for scleroderma using the Scleroderma Health Assessment Questionnaire, the Modified Rodnan Skin Score, the Scleroderma UK Functional Score, the Patient and Physician Global Assessment (VAS), the SF-36 (Short form 36) and the MRC Sum Score.